1	E	7C>6	
(°)	OEC 19	2002	SE COMMENT
	PATENT	RAD	
	PATEMI	& RAD	9 ~

Signature

REQUEST

FOR

CONTINUED EXAMINATION (RCE) TRANSMITTAL

Subsection (b) of 35 U.S.C. § 132, effective on May 29, 2000, provides for continued examination of an utility or plant application filed on or after June 8, 1995.

See the American Inventors Protection Act of 1999 (AIPA).

•		K 13/12/Ja
Application Number	09/536,762	H, is
Filing Date	March 28, 2000	41/3
First Named Inventor	Akio YAMANISHI	
Group Art Unit	3736	
Examiner Name	Kremer, M.	
Attorney Docket Number	44319-051	

This is a Request for Continued Examination (RCE) under 37 C.F.R. § 1.114 of the above-identified application NOTE: 37 C.F.R. § is effective on May 29, 2000. If the above-identified application was filed prior to May 29, 2000, applicant may wish to consider filing a continued prosecution application (CPA) under 37 C.F.R. § 1.53 (d) (PTO/SB/29) instead of a RCE to be eligible for the patent term adjustment provisions of the AIPA. See Changes to Application Examination and Provisional Application Practice, Interim Rule, 65 Fed. Reg. 14865 (Mar. 20, 2000), 1233 Off. Gaz. Pat. Office 47 (Apr. 11, 2000), which established RCE practice. polication application (s. 7) The previously submitted

i. Consider the amendment(s)/reply under 37 C.F.R. § 1.116 previously filed on TECHNOLOGY CENTER R3700 established RCE practice 1. Submission required under 37 C.F.R. § 1.114 a. 🦳 ii. Consider the arguments in the Appeal Brief or Reply Brief previously filed on___ ☐ Other **Enclosed** b. 🔯 i. Reply Amendment/Reply 12/20/2002 SFELEKE1 00000092 500417 09536762 ii. Affidavit(s)/Declaration(s) 01 FC:1801 740.00 CH ☐ Information Disclosure Statement (IDS) 810.00 CH 2. Miscellaneous Suspension of action of the above-identified application is requested under 37 C.F.R. § a. 🗀 1.1.03(c) for a period of months. (Period of suspension shall not exceed 3 months; Fee under 37 C.F.R. § 1.17(i) required) Other The RCE fee under 37 C.F.R. § 1.17(e) is required by 37 C.F.R. § 1.114 when the RCE is filed. a. X The Director is hereby authorized to charge the following fees, or credit any overpayments, to Deposit Account No. 500417. i. ⊠ RCE fee required under 37 C.F.R. § 1.17(e) <u>\$740.00</u> ii. X Extension of time fee (37 C.F.R. §§ 1.136 and 1.17) \$810.00 Other Check in the amount of \$___ enclosed Payment by credit card (Form PTO-2038 enclosed) SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED Edward J. Wise Registration No. (Attorney/Agent) 34,523 Name (Print/Type) Date December 19, 2002 Signature CERTIFICATE OF MAILING OR TRANSMISSION I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Commissioner For Parents, Box RCE, Washington, D.C. 20231, or facsimile transmitted to the U.S. Patent and Trademark Office on: Name(Print/Type) Date

DE 19 200 E

Oocket No.: 44319-051

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

1-14-03

In re Application of

Akio YAMANISHI

Serial No.: 09/536,762

,

Filed: March 28, 2000

Group Art Unit: 3736

Examiner: Kremer, M.

For: TRANSCUTANEOUS BILIRUBIN CONCENTRATION MEASURING

APPARATUS AND A MEASUREMENT DATA CHECKING PLATE FOR USE

WITH THE SAME

AMENDMENT WITH RCE

RECEIVED
DEC 2 4 2002

Assistant Commissioner for Patents Washington, DC 20231

TECHNOLOGY CENTER ROTCO

Sir:

The following amendment and remarks are submitted with the filing of the RCE.

IN THE CLAIMS

Please amend claim 1 as follows:

- 1. (Twice Amended) A bilirubin concentration measuring apparatus, comprising:
- a light emitter for emitting a light which includes a first luminous flux falling in a first wavelength range and a second luminous flux falling in a second wavelength range, their bilirubin absorption coefficients differing from each other;
- a light emerging port for projecting the light including the first and second luminous fluxes onto skin of a person;